Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Amylin Pharmaceuticals, Inc.

Loading...
Loading...
Bristol-Myers Squibb Company
BMY
announced today the successful completion of the tender offer by Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc.
AMLN
(“Amylin”) at a purchase price of $31.00 per share. As of the expiration of the offer, 140,550,153 shares of common stock of Amylin were validly tendered and not withdrawn in the tender offer. All of such shares have been accepted for payment in accordance with the terms of the tender offer. The tender offer expired at 5:00 p.m., New York City time, on August 7, 2012. As a result of the tender offer, Bristol-Myers Squibb now owns, together with its subsidiaries, approximately 85.55% of the outstanding shares of Amylin.
Posted In: NewsM&APress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...